Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339104 · ClinicalTrials.gov registry record · Phase 1
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01339104 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 53 participants.
The verdict
NCT01339104, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Open label Phase I study of Regorafenib to evaluate cardiovascular safety, tolerability and anti-tumor activity in patients with advanced solid tumors
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339104
The ClinicalTrials.gov registry entry for NCT01339104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT01339104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01339104 about?
NCT01339104 is a clinical study titled "Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity". Open label Phase I study of Regorafenib to evaluate cardiovascular safety, tolerability and anti-tumor activity in patients with advanced solid tumors
What is the current status of trial NCT01339104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2011-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01339104?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT01339104?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.